PADI2 and endometrial cancer: In endometrial cancer, IGF2BP1 is a direct downstream target of peptidylarginine deiminase II (PADI2) that is required for endometrial cancer progression, and IGF2BP1 binds to the m6A sites of oncogenic SOX2 and prevents its mRNA degradation 141.